Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.013
Buy
RSI(14)
61.456
Neutral
STOCH(KDJ)(9,3,3)
51.394
Buy
ATR(14)
0.395
High Vlolatility
CCI(14)
81.199
Neutral
Williams %R
13.165
Overbought
TRIX(12,20)
0.418
Sell
StochRSI(14)
100.000
Buy
Search
CNS Pharmaceuticals Inc
CNSPAdd to Watchlist
5.760USD
+0.910+18.76%
Close 07-31 16:00（ET）Quotes delayed by 15 min
3.64MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+18.76%
5 Days
+10.13%
1 Month
+20.50%
6 Months
+3.23%
Year to Date
+9.71%
1 Year
-27.82%
Key Figures
4.830Open
5.817High
11.64KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.84%Turnover Ratio
4.850Prev. Close
4.814Low
43.53KTurnover
LossP/E Static
0.81P/B
0.00%Div Yield TTM
-179.17%ROA
13.20052wk High
2.62Volume Ratio
-14.86MNet Profit
632.52KShares
-24.1215EPS TTM
0.88Beta
-298.64%ROE
1.90052wk Low
20.67%Amplitude
--Gross Margin
3.64MMarket Cap
-0.69Reward/Risk
6.25%Risk Rate
CNS Pharmaceuticals Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
1
analysts
Buy
Current Rating
10.000
Target Price
+100.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
CNS Pharmaceuticals Inc
CNSP
1
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
5.161
Buy
MA10
5.314
Buy
MA20
5.176
Buy
MA50
4.942
Buy
MA100
4.142
Buy
MA200
5.103
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CNS Pharmaceuticals Inc Info
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Ticker SymbolCNSP
CompanyCNS Pharmaceuticals Inc
CEOClimaco (John Michael)
Websitehttps://cnspharma.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of CNS Pharmaceuticals Inc (CNSP)?
The current price of CNS Pharmaceuticals Inc (CNSP) is 5.76.
What is the symbol of CNS Pharmaceuticals Inc?
The ticker symbol of CNS Pharmaceuticals Inc is CNSP.
What is the 52-week high of CNS Pharmaceuticals Inc?
The 52-week high of CNS Pharmaceuticals Inc is 13.20.
What is the 52-week low of CNS Pharmaceuticals Inc?
The 52-week low of CNS Pharmaceuticals Inc is 1.90.
What is the market capitalization of CNS Pharmaceuticals Inc?
The market capitalization of CNS Pharmaceuticals Inc is 3.64M.
Is CNS Pharmaceuticals Inc (CNSP) currently rated as Buy, Hold, or Sell?
According to analysts, CNS Pharmaceuticals Inc (CNSP) has an overall rating of Buy, with a price target of 10.00.
What is the Earnings Per Share (EPS TTM) of CNS Pharmaceuticals Inc (CNSP)?
The Earnings Per Share (EPS TTM) of CNS Pharmaceuticals Inc (CNSP) is -35.75.